Today: 16 July 2026
UiPath (NYSE:PATH) rebound may stall as Russell rebalancing hits shorted shares
28 June 2026
2 mins read

UiPath (NYSE:PATH) rebound may stall as Russell rebalancing hits shorted shares

NEW YORK, June 28, 2026, 12:02 EDT

  • UiPath ended Friday at $10.53, gaining 6.04%. Volume was well above average.
  • Before the latest rally, short interest stood at 32.23% of float.
  • Russell index changes are set for Monday. UiPath does not have any investor events listed.

UiPath, Inc. closed Friday at $10.53, up 60 cents, or 6.04%. The last after-hours trade printed $10.57. U.S. cash equities did not open Sunday, so any Monday action picks up from there. Volume hit 66.3 million shares, which is 186% of the 65-day average, according to MarketWatch data.

Short interest has become a key figure for investors. As of June 15, short interest was at 126.25 million shares, or 32.23% of the float. On Friday, trading volume came in at about 53% of that short interest and roughly 17% of the float. MarketWatch lists the public float at 391.72 million shares.

UiPath gained 3.6% over the week, finishing Friday at $10.53 after starting the week at $10.16. Shares held even at $10.16 on Monday and Tuesday, ticked up to $10.31 Wednesday, slipped to $9.93 Thursday, and ended up Friday. Around 298 million shares changed hands for the week, according to volume data from StockAnalysis.

S&P 500 slipped 2% this week, NYSE said in its Friday note. The equal-weight S&P added 1.5%. Small-caps did better, with the S&P 600 up over 3%. The NYSE pointed to Russell reconstitution and quarter-end as reasons for some of the rotation in the market.

UiPath is in focus because Friday wasn’t a normal day for software stocks. FTSE Russell said the revamped Russell U.S. indexes will go live after the U.S. market closes on June 26, with reconstitution shifting from yearly to every six months starting in 2026. LSEG Jefferies equity analyst Steven DeSanctis described the rebalance as a “really massive trade” and noted “turnover is dramatic,” while Stephens analyst Melissa Roberts said Friday was a “key liquidity day.” Reuters

Nasdaq, Inc. reported its Closing Cross managed 4.59 billion shares totaling $334.03 billion at the Russell rebalance, setting a new high for Nasdaq-listed stocks. The exchange said about $10.6 trillion in assets track or invest in products linked to Russell U.S. indexes.

UiPath’s risk here is that some investors may take recent flow as a sign of shifted earnings sentiment. The company’s investor calendar shows no future events and already marked the June 25 annual meeting completed. Its SEC filings list a June 4 10-Q as the most recent document. UiPath, Inc.

Annual recurring revenue and buybacks are still the main focus. UiPath turned in fiscal Q1 revenue of $418 million, rising 17%. ARR was $1.901 billion, up 12%. Adjusted free cash flow hit $130 million. CEO Daniel Dines said agentic products are shifting “from pilot to production.” CFO Ashim Gupta called out “first quarter GAAP profitability for the first time.” UiPath, Inc.

UiPath gave its guidance for the next quarter and the full year. The company sees fiscal Q2 revenue between $395 million and $400 million, with ARR landing at $1.929 billion to $1.934 billion as of July 31. Looking out to fiscal 2027, UiPath expects revenue of $1.776 billion to $1.781 billion and ARR in the range of $2.058 billion to $2.063 billion.

UiPath had around $1.42 billion in cash, equivalents and marketable securities as of Friday, making up about 26% of its $5.46 billion market cap. That put the stock at roughly 2.1 times April ARR on a cash-adjusted basis. MarketWatch

UiPath has been active in the market, picking up 20.4 million Class A shares for an average of $11.47 during the quarter ended April 30. From May 1 through May 15, it added 2.4 million more shares, this time at an average of $9.63. Back in March, the board signed off on a new $500 million buyback program.

NYSE will close for the Independence Day holiday on July 3, so trading next week is a day shorter. The exchange keeps regular hours, from 9:30 a.m. to 4 p.m. ET, on open days. Monday also marks the first session of trading with the new Russell books.

Leokadia Głogulska is a financial and technology journalist at TS2.tech, covering stocks, artificial intelligence, space technology and global market developments. She graduated from Wrocław University of Economics and Business and previously worked in financial analysis before moving into business journalism. Her reporting focuses on helping readers understand the market trends, companies and technologies shaping the global economy.

Stock Market Today

  • Abbott Tops Q2, Boosts 2026 EPS Target as Strong Device Sales Continue
    July 16, 2026, 9:44 AM EDT. Abbott Laboratories beat Q2 estimates with adjusted EPS at $1.31 and $12.59 billion in revenue, ahead of forecasts for $1.28 and $12.50 billion. Growth in medical devices and cancer diagnostics fueled results. Exact Sciences brought in $919 million, lifting year-over-year sales by 13.3%. Abbott raised its 2026 adjusted EPS target to $5.45-$5.60, saying it expects to meet sales goals even with the need for 8.6%-10.5% comparable growth in the second half. Shares gained almost 4% early, after the news. Medical device revenue jumped 8.4%, with diabetes care up 9.5% as demand for continuous-glucose monitoring stayed strong. 2026 revenue guidance held at $26.62 billion to $27.09 billion.
SpaceX stock eyes $8 billion index hurdle as shares stumble in first week after IPO
Previous Story

SpaceX stock eyes $8 billion index hurdle as shares stumble in first week after IPO

Micron (NASDAQ:MU) looks to big memory contracts as stock moves into new week
Next Story

Micron (NASDAQ:MU) looks to big memory contracts as stock moves into new week

Go toTop